Add BrightSurf on Google Email

European Society of Cardiology


Nano-measurement of troponin levels proves an accurate predictor of deterioration in heart failure

A new study finds that even small changes in troponin levels can forecast worsening outcomes in heart failure patients, with accuracy comparable to traditional risk-factor prediction models. The introduction of highly sensitive troponin assays has improved detection and allowed for the identification of high-risk subgroups.

SourceEuropean Society of Cardiology·JournalEuropean Journal of Heart Failure·DateDec 13, 2010

Overtime work is bad for the heart

A long-running study of over 10,000 civil servants in London found that working overtime was associated with a 60% higher risk of heart-related problems. The study, published in the European Heart Journal, controlled for various risk factors and suggested that chronic stress may be a key mechanism behind this association.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·DateMay 11, 2010

IQ among strongest predictors of CVD -- second only to cigarette smoking in large population study

A large population study found that lower IQ scores were associated with higher rates of cardiovascular disease and total mortality, surpassing the risk linked to smoking. The study also identified other risk factors, including obesity, high blood pressure, and low physical activity.

SourceEuropean Society of Cardiology·JournalEuropean Journal of Cardiovascular Prevention & Rehabilitation·DateFeb 9, 2010

ESC press release: BMI and waist circumference

A large prospective study of over 20,000 Dutch men and women aged 20-65 found that accurately measured BMI and waist circumference can predict the risk of fatal and non-fatal cardiovascular disease. The associations between BMI and waist circumference with heart disease were equally strong, explaining half of all fatal and one quarter ...

SourceEuropean Society of Cardiology·JournalEuropean Journal of Cardiovascular Prevention & Rehabilitation·DateDec 7, 2009

Europe's device therapy use for heart failure doubles 2004-2008, some countries have low uptake

The use of implantable devices for treating heart failure increased substantially in Europe between 2004-2008, but disparities in device adoption remain. Device therapy, including ICDs and CRT, has gained acceptance as an adjunct to traditional drug treatment, with significant benefits in reducing mortality and morbidity.

SourceEuropean Society of Cardiology·JournalEuropean Journal of Heart Failure·DateNov 29, 2009

EuroHeart 2009

Research highlights striking differences in national prevention policies and cardiovascular mortality rates across EU countries, with Hungary and Greece showing highest rates. The study also found noticeable disparities in risk factor prevalence and CHD prevention policies among the 16 participating countries.

MADIT-CRT trial

The MADIT-CRT study found that CRT-D therapy reduces the risk of heart failure or death by 34% compared to ICD-only therapy, with benefits seen across various patient sub-groups. This results validate a new indication for CRT-D therapy in preventing heart failure in at-risk patients.

AMI: The scale of the problem

Acute myocardial infarction (AMI) is a leading cause of death in the Western world, with prevalence expected to rise in developing countries. Primary PCI can open more vessels than thrombolytic therapy, saving more lives but requiring specialized facilities and collaboration.

PreSCD II registry

The PreSCD II registry found that patients protected by an implantable cardioverter defibrillator after a heart attack showed a non-significant lower mortality rate. In those with severely reduced heart function, mortality was reduced by 47% in patients with ICD implantation one month or more after MI.

PROTECT study

The PROTECT trial found that rolofylline had no significant effect on primary or secondary end-points in patients with acute heart failure, including dyspnea improvement and persistent renal impairment. The study did show an increased risk of neurological events in rolofylline-treated patients.

Results from the European CRT survey

The survey enrolled 2438 patients with a mean age of 68 years, showing characteristic differences between those receiving CRT-P and CRT-D devices. Demographic and economic factors play a significant role in device selection, with younger patients, men, and those with ischaemic aetiology more likely to receive a CRT-D device.

Results from the Kyoto heart study

The KYOTO HEART Study found that valsartan significantly reduced the incidence of cardiovascular events, including angina pectoris and stroke/TIA, in Japanese hypertensive patients. The study showed a lower rate of primary endpoints in the valsartan arm compared to non-ARB conventional therapies.